IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1301-1325 out of 1372.

<< < 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 > >>

Public Release: 10-Feb-2015
Journal of Clinical Oncology
Smaller pre-surgery radiation targets reduces long term side effects, not survival rates
The Journal of Clinical Oncology just published clinical trial results that more firmly establish that for patients with soft tissue sarcomas, image-guided radiation directed towards a smaller target area great reduced long term negative impact without effecting survival rates.
NRG Oncology

Contact: Charles Jolie
Rush University Medical Center

Public Release: 10-Feb-2015
Plain packaging reduces 'cigarette-seeking' response by almost 10 percent, says study
Plain tobacco packaging may reduce the likelihood of smokers seeking to obtain cigarettes by almost 10 percent compared to branded packs, according to research from the universities of Exeter and Bristol.
British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, National Institute for Health Research

Contact: Eleanor Gaskarth
University of Exeter

Public Release: 10-Feb-2015
Molecular Cancer Therapeutics
Lung cancer may be treatable with use of SapC-DOPS technology, research shows
A University of Cincinnati study, published in the advance online edition of the journal Molecular Cancer Therapeutics, provides hope that the therapeutic agent SapC-DOPS could be used for treatment of this cancer.
NIH/National Cancer Institute, New Drug State Key Project, University of Cincinnati College of Medicine

Contact: Katie Pence
University of Cincinnati Academic Health Center

Public Release: 10-Feb-2015
British Journal of Cancer
90 percent approve of cancer screening but screening uptake is lower
Nine in 10 people think that cancer screening is 'almost always a good idea' despite the fact that screening uptake is lower, a Cancer Research UK study in the British Journal of Cancer shows.

Contact: Emily Head
Cancer Research UK

Public Release: 9-Feb-2015
Southern Surgical Association 126th Annual Meeting
Journal of the American College of Surgeons
Many mastectomy patients with locally advanced breast cancer do not get postop radiation
Breast cancer patients who undergo a mastectomy should receive subsequent radiation treatment if their cancer has spread to four or more nearby lymph nodes, however, according to a new study, only 65 percent of these women are getting the recommended postmastectomy radiation therapy.
Louisiana State University Charles Knight Sr. Endowed Professorship

Contact: Sally Garneski
American College of Surgeons

Public Release: 9-Feb-2015
Nature Communications
What autism can teach us about brain cancer
Applying lessons learned from autism to brain cancer, researchers at The Johns Hopkins University have discovered why elevated levels of the protein NHE9 add to the lethality of the most common and aggressive form of brain cancer, glioblastoma. Their discovery suggests that drugs designed to target NHE9 could help to successfully fight the deadly disease.
NIH/National Institute of Neurological Disorders and Stroke, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, American Heart Association, Johns Hopkins Post-Baccalaureate Research Education Program

Contact: Catherine Kolf
Johns Hopkins Medicine

Public Release: 9-Feb-2015
Study identifies 8 signs associated with impending death in cancer patients
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published in the journal Cancer, could offer clinicians the ability to better communicate with patients and families. They may also guide both the medical team and caregivers on complex decision making, such as discontinuation of tests and therapy, plans for hospital discharge and hospice referral.

Contact: Laura Sussman
University of Texas M. D. Anderson Cancer Center

Public Release: 9-Feb-2015
A new opportunity to treat drug-resistant leukemia discovered
An international joint effort between University of Helsinki and Pfizer researchers has led to the discovery of a new opportunity to treat drug-resistant leukemia with an approved renal cancer drug.

Contact: Krister Wennerberg
University of Helsinki

Public Release: 9-Feb-2015
JAMA Internal Medicine
HPV vaccination not linked to riskier sex
Receiving the HPV vaccine does not increase rates of sexually transmitted infections in adolescent females, suggesting that vaccinating girls is not likely to promote unsafe sexual activity.
National Institutes of Health, NIH/National Institute on Aging

Contact: David Cameron
Harvard Medical School

Public Release: 9-Feb-2015
Nature Biotechnology
Computer model of blood development could speed up search for new leukaemia drugs
The first comprehensive computer model to simulate the development of blood cells could help in the development of new treatments for leukaemia and lymphoma, say researchers at the University of Cambridge and Microsoft Research.
Medical Research Council, Biotechnology and Biological Sciences Research Council, Leukaemia and Lymphoma Research, Leukemia and Lymphoma Society, Microsoft Research, Wellcome Trust

Contact: Craig Brierley
University of Cambridge

Public Release: 9-Feb-2015
Study identifies clinical signs suggestive of impending death in patients with advanced cancer
While the diagnosis of an impending death is always sad, it can be important for patients, families, and clinicians as they make decisions related to hospital discharge, hospice referral, and treatments.

Contact: Evelyn Martinez

Public Release: 9-Feb-2015
Cancer Epidemiology, Biomarkers, and Prevention
Study links new genetic anomalies to breast cancer in African-American families
Researcher Heather Ochs-Balcom says, 'Our family-based gene hunt is similar to the groundbreaking study among women with European ancestry done in the early 1990s that led to the discovery of BRCA1 and BRCA2 gene mutations, which greatly increase susceptibility to breast and ovarian cancer.'

Contact: Patricia Donovan
University at Buffalo

Public Release: 9-Feb-2015
Nature Genetics
UCSF-led study shows why some targeted cancer drugs lose effectiveness
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
NIH Director's New Innovator Award, Howard Hughes Medical Institute, Doris Duke Charitable Foundation, American Lung Association, National Lung Cancer Partnership, Sidney Kimmel Foundation for Cancer Research, Searle Scholars Program

Contact: Pete Farley
University of California - San Francisco

Public Release: 9-Feb-2015
Cancer Cell
'Jekyll and Hyde'protein both prevents and spreads cancer
Scottish author Robert Louis Stevenson tapped into primal fears when he penned 'Dr. Jekyll and Mr. Hyde,' a 19th century novel about a sinister physician, raising the question, 'Can evil and good exist in the same person?'

Contact: Ron Gilmore
University of Texas M. D. Anderson Cancer Center

Public Release: 9-Feb-2015
Cancer Epidemiology, Biomarkers & Prevention
Previously unknown genomic regions found in African American families with breast cancer
Study led by University at Buffalo has uncovered previously unknown segments of DNA shared by African American family members who have breast cancer. The discovery of these regions supports our hypothesis that there are still undiscovered breast cancer genes that may be unique to African and spurs researchers to focus on these specific chromosomes to learn if they house genetic mutations linked to breast cancer
Susan Komen for the Cure Foundation

Contact: Pat Donovan
University at Buffalo

Public Release: 9-Feb-2015
Journal of National Cancer Institute
Study finds no reason for cancer survivors to be excluded in advanced stage lung cancer trials
The common practice of excluding patients with a prior cancer diagnosis from lung cancer clinical trials may not be justified, according to a study by researchers from UT Southwestern Medical Center.

Contact: Lori Sundeen Soderbergh
UT Southwestern Medical Center

Public Release: 9-Feb-2015
Clinical Cancer Research
Could there be a gleevec for brain cancer?
The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth.
NIH/National Institute of Neurological Disorders and Stroke

Contact: Karin Eskenazi
Columbia University Medical Center

Public Release: 9-Feb-2015
Nature Communications
New screening tool could speed development of ovarian cancer drugs
Researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in the spread of ovarian cancer. Their 3-D cell culture system has enabled them to identify small molecules that can inhibit adhesion and invasion, hallmarks of cancer metastasis.
Bears Care, National Institutes of Health, NIH/National Cancer Institute, NIH/National Institute of Neurological Disorders and Stroke

Contact: John Easton
University of Chicago Medical Center

Public Release: 9-Feb-2015
Cell Metabolism
Griffith research unlocks more about cancer
Ground-breaking research from Griffith University on the Gold Coast has some scientists wondering if the entire study of cellular biology needs to be adjusted.
Malaghan Institute of New Zealand, Griffith University

Contact: Louise Durack
Griffith University

Public Release: 9-Feb-2015
ASTRO applauds CMS's decision to cover annual, LDCT screening for high-risk lung cancer patients
The American Society for Radiation Oncology commends the Febr. 5, 2015, decision by the Centers for Medicare and Medicaid Services to provide coverage for annual lung cancer screening via low-dose CT screening for those at highest-risk for lung cancer.

Contact: Michelle Kirkwood
American Society for Radiation Oncology

Public Release: 9-Feb-2015
Annals of Internal Medicine
Lung screening guidelines improve on study findings
A set of guidelines developed to help standardized lung cancer screening would have generated considerably fewer false-positives than the National Lung Screening Trial produced, according to a new retrospective study.
National Institutes of Health

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 9-Feb-2015
Journal of Clinical Investigation
Cancer's ability to 'hijack' regulatory mechanism increases metastasis
When skyscrapers go up, contractors rely on an infrastructure of steel beams and braces. Some cancers grow the same way, using a biological matrix from which the tumor can thrive and spread.

Contact: Ron Gilmore
University of Texas M. D. Anderson Cancer Center

Public Release: 9-Feb-2015
Nature Genetics
Keck Medicine of USC researchers trace origins of colorectal cancer tumor cells
For the first time, Keck Medicine of the University of Southern California cancer researchers have traced the origins of colorectal cancer cells, finding important clues to why tumor cells become 'good' or 'bad,' with the potential of stopping them before they start.
National Cancer Institute, The V Foundation for Cancer Research

Contact: Leslie Ridgeway
University of Southern California - Health Sciences

Public Release: 9-Feb-2015
Nature Genetics
Inherited gene variations tied to treatment-related hearing loss in cancer patients
St. Jude Children's Research Hospital investigators have discovered inherited genetic variations that are associated with rapid hearing loss in young cancer patients treated with the drug cisplatin. The research appears in the current online issue of the scientific journal Nature Genetics.
National Institutes of Health, ALSAC

Contact: Carrie Strehlau
St. Jude Children's Research Hospital

Public Release: 9-Feb-2015
Journal of Experimental Medicine
How tumor-causing cells are recruited in cancers linked to chronic inflammation
Chronic inflammation is directly associated with several types of cancer, yet the reasons as to why this happens at a cellular level remain unclear. Now, an international team of scientists led by researchers at The Wistar Institute has identified a multistep process showing not only how these cancers develop but also potentially discovering new therapeutic targets that could halt the formation and progression of tumor cells.
National Institutes of Health

Contact: Ben Leach
The Wistar Institute

Showing releases 1301-1325 out of 1372.

<< < 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 > >>

  Search News Releases